iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://statista.com/statistics/1301122/covid-vaccines-comparison-by-efficacy/
Select COVID-19 vaccines by efficacy 2022 | Statista

Comparison of select COVID-19 vaccines 2022, by efficacy

Published by
Matej Mikulic,
Mar 7, 2023
As of February 2022, mRNA-based vaccine Comirnaty, developed by Pfizer/Biontech, was the leading COVID-19 vaccine by efficacy rate, showing around 95 percent of efficacy against COVID-19. This statistic illustrates the comparison of select COVID-19 vaccines worldwide, by efficacy.

Comparison of select COVID-19 vaccines worldwide as of 2022, by efficacy

Loading statistic...

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2022

Region

Worldwide

Survey time period

as of February 2022

Supplementary notes

Efficacy figures based on phase 3 studies when different variants were prominent.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Moderna Inc. "

The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Moderna Inc.

Market overview

6

Key figures

5

Competitors

4

Focus: COVID-19

8

Further Content: You might find this interesting as well

Topics

Global pharmaceutical industryPfizerBioNTechVaccinations in the U.S.Coronavirus disease (COVID-19) pandemic
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.